1. Germing U, Schroeder T, Kaivers J, Kündgen A, Kobbe G, Gattermann N. Novel therapies in low- and high-risk myelodysplastic syndrome. Expert Rev Hematol. 2019;12:893–908.
2. Anderson KC. Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol. 2005;42:4 Suppl 4. S3–8.
4. Barth P, Giri S, Reagan JL, Olszewski AJ. Outcomes of lenalidomideor bortezomib-based regimens in older patients with plasma cell myeloma. Am J Hematol. 2021;96:14–22.
5. Warren KE, Goldman S, Pollack IF, et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: pediatric brain tumor consortium study PBTC-018. J Clin Oncol. 2011;29:324–9.
8. Palencia G, Calderon A, Sotelo J. Thalidomide inhibits pentylenetetrazole-induced seizures. J Neurol Sci. 2007;258:128–31.
9. Palencia G, Rubio C, Custodio-Ramirez V, Paz C, Sotelo J. Strong anticonvulsant effect of thalidomide on amygdaloid kindling. Epilepsy Res. 2011;95:263–9.
10. Pourshadi N, Rahimi N, Ghasemi M, et al. anticonvulsant effects of thalidomide on pentylenetetrazole-induced seizure in mice: a role for opioidergic and nitrergic transmissions. Epilepsy Res. 2020;164:106362
11. Ladizinski B, Shannon EJ, Sanchez MR, Levis WR. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. J Drugs Dermatol. 2010;9:814–26.
12. Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma. 2008;49:1238–45.
13. Khan MI, Momeny M, Ostadhadi S, et al. Thalidomide attenuates development of morphine dependence in mice by inhibiting PI3K/Akt and nitric oxide signaling pathways. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:39–48.
14. Javadian N, Rahimi N, Javadi-Paydar M, Doustimotlagh AH, Dehpour AR. The modulatory effect of nitric oxide in pro- and anti-convulsive effects of vasopressin in PTZ-induced seizures threshold in mice. Epilepsy Res. 2016;126:134–40.
15. Hassanipour M, Shirzadian A, Boojar MM, et al. Possible involvement of nitrergic and opioidergic systems in the modulatory effect of acute chloroquine treatment on pentylenetetrazol induced convulsions in mice. Brain Res Bull. 2016;121:124–30.
16. Gholipour T, Ghasemi M, Riazi K, Ghaffarpour M, Dehpour AR. Seizure susceptibility alteration through 5-HT(3) receptor: modulation by nitric oxide. Seizure. 2010;19:17–22.
17. Ghasemi M, Shafaroodi H, Nazarbeiki S, et al. Inhibition of NMDA receptor/ NO signaling blocked tolerance to the anticonvulsant effect of morphine on pentylenetetrazole-induced seizures in mice. Epilepsy Res. 2010;91:39–48.
18. Mares P, Velísek L. N-methyl-D-aspartate (NMDA)-induced seizures in developing rats. Brain Res Dev Brain Res. 1992;65:185–9.
19. Rahimi N, Sadeghzadeh M, Javadi-Paydar M, Heidary MR, Jazaeri F, Dehpour AR. Effects of D-penicillamine on pentylenetetrazole-induced seizures in mice: involvement of nitric oxide/NMDA pathways. Epilepsy Behav. 2014;39:42–7.
20. Bahramnjead E, Kazemi Roodsari S, Rahimi N, Etemadi P, Aghaei I, Dehpour AR. Effects of modafinil on clonic seizure threshold induced by pentylenetetrazole in mice: involvement of glutamate, nitric oxide, GABA, and serotonin pathways. Neurochem Res. 2018;43:2025–37.
21. Robello M, Amico C, Bucossi G, Cupello A, Rapallino MV, Thellung S. Nitric oxide and GABAA receptor function in the rat cerebral cortex and cerebellar granule cells. Neuroscience. 1996;74:99–105.
22. Payandemehr B, Rahimian R, Gooshe M, et al. Nitric oxide mediates the anticonvulsant effects of thalidomide on pentylenetetrazole-induced clonic seizures in mice. Epilepsy Behav. 2014;34:99–104.
23. Ghasemi M. Nitric oxide: a ntidepressant mechanisms and inflammation. Adv Pharmacol. 2019;86:121–52.
24. Ghasemi M, Mayasi Y, Hannoun A, Eslami SM, Carandang R. Nitric oxide and mitochondrial function in neurological diseases. Neuroscience. 2018;376:48–71.
25. Ghasemi M, Claunch J, Niu K. Pathologic role of nitrergic neurotransmission in mood disorders. Prog Neurobiol. 2019;173:54–87.
26. Leppik IE, Dreifuss FE, Pledger GW, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology. 1991;41:1785–9.
27. Corbett JA, McDaniel ML. The use of aminoguanidine, a selective iNOS inhibitor, to evaluate the role of nitric oxide in the development of auto-immune diabetes. Methods. 1996;10:21–30.
29. Luo J, Gagne JJ, Landon J, Avorn J, Kesselheim AS. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: a population-based cohort study. Eur J Cancer. 2017;70:22–33.
30. Bergstroem R, Bergström L, Putkonen P, Sainio K. The effects of thalidomide on the electrical activity of the brain in the intrauterine guinea-pig foetus. Med Exp Int J Exp Med. 1964;11:119–27.
31. Kaitin KI. Effects of thalidomide and pentobarbital on neuronal activity in the preoptic area during sleep and wakefulness in the cat. Psychopharmacology (Berl). 1985;85:47–50.
32. Palencia G, Martinez-Juarez IE, Calderon A, Artigas C, Sotelo J. Thalidomide for treatment of refractory epilepsy. Epilepsy Res. 2010;92:253–7.
34. Noguchi T, Sano H, Shimazawa R, Tanatani A, Miyachi H, Hashimoto Y. Phenylhomophthalimide-type NOS inhibitors derived from thalidomide. Bioorg Med Chem Lett. 2004;14:4141–5.
35. Ahmed MM, Arif M, Chikuma T, Kato T. Pentylenetetrazol-induced seizures affect the levels of prolyl oligopeptidase, thimet oligopeptidase and glial proteins in rat brain regions, and attenuation by MK-801 pretreatment. Neurochem Int. 2005;47:248–59.
36. Ghasemi M, Dehpour AR. The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium. Trends Pharmacol Sci. 2011;32:420–34.
37. Buisson A, Lakhmeche N, Verrecchia C, Plotkine M, Boulu RG. Nitric oxide: an endogenous anticonvulsant substance. Neuroreport. 1993;4:444–6.
38. Starr MS, Starr BS. Paradoxical facilitation of pilocarpine-induced seizures in the mouse by MK-801 and the nitric oxide synthesis inhibitor L-NAME. Pharmacol Biochem Behav. 1993;45:321–5.
39. Theard MA, Baughman VL, Wang Q, Pelligrino DA, Albrecht RF. The role of nitric oxide in modulating brain activity and blood flow during seizure. Neuroreport. 1995;6:921–4.
40. Mülsch A, Busse R, Mordvintcev PI, et al. Nitric oxide promotes seizure activity in kainate-treated rats. Neuroreport. 1994;5:2325–8.
41. Nidhi G, Balakrishnan S, Pandhi P. Role of nitric oxide in electroshock and pentylenetetrazole seizure threshold in rats. Methods Find Exp Clin Pharmacol. 1999;21:609–12.
42. Osonoe K, Mori N, Suzuki K, Osonoe M. Antiepileptic effects of inhibitors of nitric oxide synthase examined in pentylenetetrazol-induced seizures in rats. Brain Res. 1994;663:338–40.
43. Mollace V, Bagetta G, Nisticò G. Evidence that L-arginine possesses proconvulsant effects mediated through nitric oxide. Neuroreport. 1991;2:269–72.
44. Homayoun H, Khavandgar S, Namiranian K, Gaskari SA, Dehpour AR. The role of nitric oxide in anticonvulsant and proconvulsant effects of morphine in mice. Epilepsy Res. 2002;48:33–41.
45. Zamanian G, Shayan M, Rahimi N, et al. Interaction of morphine tolerance with pentylenetetrazole-induced seizure threshold in mice: the role of NMDA-receptor/NO pathway. Epilepsy Behav. 2020;112:107343
46. Meskinimood S, Rahimi N, Faghir-Ghanesefat H, Gholami M, Sharifzadeh M, Dehpour AR. Modulatory effect of opioid ligands on status epilepticus and the role of nitric oxide pathway. Epilepsy Behav. 2019;101:Pt A. 106563
47. Rondouin G, Bockaert J, Lerner-Natoli M. L-nitroarginine, an inhibitor of NO synthase, dramatically worsens limbic epilepsy in rats. Neuroreport. 1993;4:1187–90.
48. Maggio R, Fumagalli F, Donati E, et al. Inhibition of nitric oxide synthase dramatically potentiates seizures induced by kainic acid and pilocarpine in rats. Brain Res. 1995;679:184–7.
49. Wang Q, Theard MA, Pelligrino DA, et al. Nitric oxide (NO) is an endogenous anticonvulsant but not a mediator of the increase in cerebral blood flow accompanying bicuculline-induced seizures in rats. Brain Res. 1994;658:192–8.
50. Del-Bel EA, Oliveira PR, Oliveira JA, Mishra PK, Jobe PC, Garcia-Cairasco N. Anticonvulsant and proconvulsant roles of nitric oxide in experimental epilepsy models. Braz J Med Biol Res. 1997;30:971–9.
51. De Sarro G, Di Paola ED, De Sarro A, Vidal MJ. L-arginine potentiates excitatory amino acid-induced seizures elicited in the deep prepiriform cortex. Eur J Pharmacol. 1993;230:151–8.
52. Penix LP, Davis W, Subramaniam S. Inhibition of NO synthase increases the severity of kainic acid-induced seizures in rodents. Epilepsy Res. 1994;18:177–84.
53. Wink DA, Miranda KM, Espey MG. Cytotoxicity related to oxidative and nitrosative stress by nitric oxide. Exp Biol Med (Maywood). 2001;226:621–3.
55. Ghasemi M, Schachter SC. The NMDA receptor complex as a therapeutic target in epilepsy: a review. Epilepsy Behav. 2011;22:617–40.
56. Choi YB, Tenneti L, Le DA, et al. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat Neurosci. 2000;3:15–21.
57. Lee YI, Giovinazzo D, Kang HC, et al. Protein microarray characterization of the S-nitrosoproteome. Mol Cell Proteomics. 2014;13:63–72.
58. Lipton SA, Choi YB, Takahashi H, et al. Cysteine regulation of protein function--as exemplified by NMDA-receptor modulation. Trends Neurosci. 2002;25:474–80.
59. Ghasemi M, Shafaroodi H, Nazarbeiki S, et al. Voltage-dependent calcium channel and NMDA receptor antagonists augment anticonvulsant effects of lithium chloride on pentylenetetrazole-induced clonic seizures in mice. Epilepsy Behav. 2010;18:171–8.
60. Tran HQ, Chung YH, Shin EJ, et al. MK-801, but not naloxone, attenuates high-dose dextromethorphan-induced convulsive behavior: possible involvement of the GluN2B receptor. Toxicol Appl Pharmacol. 2017;334:158–166.
61. Reeta Kh, Prabhakar P, Gupta YK. Anticonvulsant activity of the antidepressant drug, tianeptine, against pentylenetetrazole-induced seizures mitigates cognitive impairment in rats. Behav Pharmacol. 2016;27:623–32.
62. O'Neill SK, Bolger GT. Anticonvulsant activity of MK-801 and nimodipine alone and in combination against pentylenetetrazole and strychnine. Pharmacol Biochem Behav. 1989;32:595–600.
64. Turski WA, Cavalheiro EA, Bortolotto ZA, Ikonomidou C, Turski L. Anticonvulsant activity of N-methyl-D-aspartate in the rat substantia nigra pars compacta. Cavalheiro EA, Lehmann J, Turski L, editors. Frontiers in Excitatory Amino Acid Research. New York: Liss; 1988. p. 263–266.
65. Teo SK, Evans MG, Brockman MJ, et al. Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs. Toxicol Sci. 2001;59:160–8.
66. FINCATO M. Potentiating effect of N-phthalyl-glutamic acid imide on barbiturate-induced sleep. Boll Soc Ital Biol Sper. 1957;33:872–4.
67. Velíšek L. Models of chemically-induced acute seizures. Pitkanen A, Schwartzkroin PA, Moshé SL, editors. Models of Seizures and Epilepsy. Amsterdam: Elsevie; 2006. p. 127–152.